Highlights

  • Sigma Healthcare (ASX:SIG) reported FY26 Revenue of AUD 10.8 billion, up 15.5% on its comparable pro forma basis.
  • The first full financial year after the Chemist Warehouse combination delivered normalised EBIT of AUD 1.09 billion.
  • The company reported AUD 32.6 million of delivered integration synergies and retained its FY29 annual target.
  • Its October 2026 AGM included a trading update covering the enlarged pharmacy and distribution business.

Sigma Healthcare (ASX:SIG) operates a pharmacy retail network and pharmaceutical distribution activities, including Chemist Warehouse and other pharmacy formats in Australia and overseas. Its network plan, Brand development and logistics arrangements were central to the October Shareholder updates. Its ASX-listed shares traded at AUD 2.895 on 20 November 2026, up 0.17% in the session.

October AGM Focuses on Store Openings

The 26 August full-year results described the first completed financial year following the Chemist Warehouse combination. Revenue increased 15.5% to AUD 10.8 billion against the company’s normalised pro forma comparison. Network development spans Australian stores and international operations. Rather than assuming that proposed openings have occurred, subsequent reporting needs to distinguish new locations from established stores and show actual trading contributions.

Synergies and Operating Model

The FY26 results reported AUD 32.6 million in integration synergies delivered and a goal of AUD 100 million per annum by FY29. The delivered amount and future annual target represent different reporting measures. Integration can involve common procurement, technology, distribution, own-label merchandise and administrative functions.

Its FY26 announcement also identified development across its Australian and international operating segments. Those initiatives may change the revenue mix and operating costs, but an announced synergy target is not a realised Earnings figure. Subsequent interim statements can provide the information on benefits already reflected in results.

FY26 Context and the Reporting Boundary

The August results reported normalised EBIT of AUD 1,090.0 million, up 20.6%, and normalised net profit of AUD 732.3 million, up 22.3%. Net Debt was AUD 663 million, equivalent to 0.57 times normalised EBITDA. These growth rates compare against normalised pro forma FY25 amounts, not a conventional unadjusted statutory base. These statements were management guidance and should be evaluated against the relevant reporting period rather than assumed to have been achieved.

The October AGM included a trading update following that results presentation. A full assessment depends on comparable store sales, international openings, distribution margins and operating costs, not simply the number of branded pharmacy locations.

Financial Performance and Integration

The FY26 results reported a 14.9% increase in Australian segment revenue and an 18.3% rise in normalised Australian EBIT. International normalised EBIT increased 91.3% to AUD 55.8 million. Management also reported that the Ireland Business was profitable for the first time. These reported outcomes should be distinguished from proposed store openings and estimated future synergies.

Risks to Consider

Pharmacy Retailing operates within health regulation, prescription dispensing arrangements and consumer spending conditions. Execution considerations include store opening schedules, recruitment, system integration, Lease commitments and supplier agreements. Competition in retail pharmacy can affect pricing and mix.

Changes to pharmaceutical reimbursement and government policy may affect trading economics, while overseas expansion introduces unfamiliar regulatory and operational requirements. Forecast synergies depend on practical changes reaching operating profit after the associated costs.

What to Watch Next

The immediate checkpoints are store openings, comparable sales and integration updates for the first half of FY27. A reader can also assess the contribution of the new international pharmacies separately from Australian network growth.

Further company statements may quantify realised synergies and clarify the timing of expenditure. The next reporting release will provide a firmer test of the operating assumptions presented in August and October.

Key Insights

Network expansion and post-combination integration are the main themes. The reported synergies and FY29 target establish different milestones, while subsequent reporting must distinguish completed actions from plans and show their financial effect.